Epidemiological Justification for Systems-Level Health Policies to Reduce Mississippi Infant Deaths
Methods: The study included 399 in-hospital infant deaths from 2010-2011 Mississippi hospital discharge data. Statistical analyses using SAS 9.3 included descriptive statistics and Chi-square testing. Medical conditions were examined as primary or secondary diagnoses.
Results: A disproportionate number of cases were African American (68.4%), rural residents (66.2%), and Medicaid beneficiaries (74.0%). African-Americans were more likely to have Medicaid (84.3% versus 51.6%, p < 0.001). Nearly one third of cases (29.3%) died during the first day of life. An additional 13.8% died during the first week. Over 61% of all cases expired during the first month. Over half deaths (58.0%) occurred among infants transferred from another health care facility. Short gestation/low birth weight were the leading morbidities (55.1%). Additional morbidities included congenital anomalies (33.8%), sepsis (22.8%), respiratory distress syndrome (21.1%), and maternal causes (15.3%). Hospital charges for the group exceeded $22 million.
Conclusion: In addition to racial, residential, and socioeconomic disparities, results revealed excess deaths among infants transferred from another facility. Findings confirm the need for better access to high risk health care for mothers and infants. Health policies that revisit previous perinatal regionalization efforts are warranted to improve infant survival rates.
Implications for Public Health: Systems-level changes require epidemiological justification.
Learning Areas:Public health or related laws, regulations, standards, or guidelines
Public health or related public policy
Describe morbidity and hospital use among 2010-2011 Mississippi in-hospital infant deaths
Keyword(s): Health Care Costs, Infant Mortality
Qualified on the content I am responsible for because: Multiple years of experience working with Mississippi hospital discharge data.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.